Daniel Castellano
Universidad Complutense de Madrid(ES)Research Institute Hospital 12 de Octubre(ES)Hospital Universitario 12 De Octubre(ES)
Publications by Year
Research Areas
Bladder and Urothelial Cancer Treatments, Cancer Immunotherapy and Biomarkers, Renal cell carcinoma treatment, Urinary and Genital Oncology Studies, Prostate Cancer Treatment and Research
Most-Cited Works
- → Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma(2015)5,840 cited
- → Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma(2018)4,537 cited
- → Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial(2016)3,687 cited
- → Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial(2011)1,839 cited
- → Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study(2020)1,787 cited
- → Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial(2017)